
AbbVie, ADCs and the future of cancer care
The Top Line
00:00
Advancements in Targeting CMET Overexpression in Cancer Treatment
This chapter explores a breakthrough in cancer treatment through the use of TMAPA, a second-generation antibody-drug conjugate targeting CMET overexpression. It highlights encouraging clinical data demonstrating high response rates in patients with non-small cell lung and colorectal cancers, emphasizing its potential to enhance outcomes in challenging cases.
Transcript
Play full episode